TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03121573

Intervention type: DRUG
Group type: OTHER
Intervention: Duloxetine
Description: duloxetine 30 to 60 mg tablets by mouth, QD to BID per day,
Study: NCT02397434

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Adjuvant EBRT
Description: Radiation up to a median dose of 50 Gy in 25 fractions will be delivered with IMAT to the pelvic lymph node regions. If there is a positive surgical margin, the operative bladder bed will be included in the radiation field. A simultaneous integrated boost to positive lymph nodes will be delivered.
Study: NCT01225289

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin A
Description: 25000 IU/day (one capsule per day) Vitamin A for 6 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 capsule per day for six months
Study: NCT04875689

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group A (Experimental
Description: Laser therapy is performed on patients in supine lying position. Treatments will be delivered with a diode laser (wavelength 830 nm, continuous wave, power 50 mW) in skin contact at a dose of 6 J/point. Treatment times per point are in the range of 30 seconds to 1 minute. eight points were irradiated per session.~Conventional therapy will include:~* TENS for 15 minutes~* Hot pack for 15 minutes~* Hamstrings muscle stretching and calf muscle stretching. Strengthening exercises ,straight leg raising exercise in crook lying position~* Joint mobilizations

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Group B (Control)
Description: 1. Participants of this group will receive only conventional therapy which will include;~* TENS for 15 minutes~* Hot pack for 15 minutes~* Hamstrings muscle stretching and calf muscle stretching.Each stretch was sustained for 30 seconds, with 10-second rest intervals.~* Strengthening exercises include quadricep drills(full knee extension maintained for 5 seconds, followed by a 5-second rest) 20 repetitions per session,straight leg raising exercise in crook lying position(the patients were asked to tense the quadriceps muscle, elevate the limb to 45° and maintain it for 6 seconds, and lower the limb slowly and then relax for 6 seconds; the exercise was performed for three sets of 10 repetitions per session).~* Joint mobilizations (tibiofemoral extension and flexion; patellofemoral medial-lateral and inferior glide).
Study: NCT03602833

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Compound 451238
Description: Each patient will receive compound 451238 until disease progression unacceptable toxicities.
Study: NCT01110668

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nilotinib
Study: NCT04135066

Intervention type: OTHER
Group type: OTHER
Intervention: Refine grain breakfast
Description: After wearing continuous glucose monitoring device (CGM) on baseline, participants will be provided with breakfast A on two consecutive days in a whoe 14-day monitoring period. The appearance of breakfast A is pseudorandom. Breakfast A contains white bread (100g) and milk powder (25g). Since lunch and dinner would serve as wash-out meals, participants will be free to choose food but provide a record of their diets.

Intervention type: OTHER
Group type: OTHER
Intervention: Whole grain breakfast
Description: After wearing CGM on baseline, participants will be provided with breakfast B on two consecutive days in a whoe 14-day monitoring period. The appearance of breakfast B is pseudorandom. Breakfast B contains plain oats (70g) and milk powder (25g). Since lunch and dinner would serve as wash-out meals, participants will be free to choose food but provide a record of their diets.
Study: NCT02552888

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Immediate release sodium nitrite
Description: Immediate release sodium nitrite 40 mg by mouth twice per day

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Isoquercetin
Description: Isoquercetin 225 mg by mouth once per day

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebos
Description: placebos
Study: NCT00553358

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lapatinib
Description: Small molecule receptor tyrosine kinase inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lapatinib
Description: Small molecule receptor tyrosine kinase inhibitor

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Trastuzumab
Description: Therapeutic Monoclonal Antibody

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Therapeutic Monoclonal Antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: antimicrotubule agent

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: antimicrotubule agent
Study: NCT02769065

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-071
Description: TAK-071 capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-071
Description: TAK-071 capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-071
Description: TAK-071 capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-071
Description: TAK-071 capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-071
Description: TAK-071 capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-071
Description: TAK-071 capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-071
Description: TAK-071 capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donepezil
Description: Donepezil over-encapsulated tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donepezil
Description: Donepezil over-encapsulated tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donepezil
Description: Donepezil over-encapsulated tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Donepezil
Description: Donepezil over-encapsulated tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donepezil
Description: Donepezil over-encapsulated tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donepezil
Description: Donepezil over-encapsulated tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donepezil
Description: Donepezil over-encapsulated tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Donepezil
Description: Donepezil over-encapsulated tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-071 Placebo
Description: TAK-071 placebo-matching capsules

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: TAK-071 Placebo
Description: TAK-071 placebo-matching capsules

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: TAK-071 Placebo
Description: TAK-071 placebo-matching capsules

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: TAK-071 Placebo
Description: TAK-071 placebo-matching capsules

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: TAK-071 Placebo
Description: TAK-071 placebo-matching capsules

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: TAK-071 Placebo
Description: TAK-071 placebo-matching capsules

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Donepezil Placebo
Description: Donepezil placebo-matching over-encapsulated tablet
Study: NCT00553358

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: antimicrotubule agent
Study: NCT01708720

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IPV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sabin-IPV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adjuvanted Sabin-IPV
Study: NCT05459194

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: RP - TA
Description: randomized, double-blind, double-dummy, placebo-controlled, 3-way crossover, single dose study, comparing the efficacy and safety of the Fluticasone/Salmeterol combination administered with Elpenhaler®db (Rolenium®) versus the innovative one (Seretide Diskus®)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: RP - TA
Description: randomized, double-blind, double-dummy, placebo-controlled, 3-way crossover, single dose study, comparing the efficacy and safety of the Fluticasone/Salmeterol combination administered with Elpenhaler®db (Rolenium®) versus the innovative one (Seretide Diskus®)
Study: NCT03881891

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Follow-app intervention arm
Description: The intervention includes implementation and evaluation of the effectiveness of a mobile phone-based text messaging system (FollowApp.Care) to collect patients' assessments of their post-op symptoms (pain intensity) and to use that data to improve their quality of care (pain experience) in the dental office setting
Study: NCT02811380

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BIP CVC
Description: BIP CVC catheterization to minimize risk of infections for venous access during and after elective large surgery

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Uncoated Standard CVC
Description: Standard CVC catheterization for venous access during and after elective large surgery
Study: NCT03380364

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: hystroscope
Description: Procedure: Hysteroscopy Office hysteroscopy will be performed during the proliferative phaseof the menstrual cycle.~All OH (office hysteroscopy) procedures will be performed with a vaginoscopic approach without utilizing a speculum and applying traction to the cervix with a tenaculum.~Antibiotic prophylaxis: None OH will be cancelled until after treatment of vaginal infection.~Other Name: ROH: Routine Office Hysteroscopy Device: Hysteroscope The device used is a rigid hysteroscope (continuous flow, 30 degree forward oblique view) assembled in a 5-mm diameter diagnostic rigid sheath with an atraumatic tip (Karl Storz Endoscopy).~Illumination: High intensity cold light source and fiberoptic cable Distention medium: solution of 0.9% normal saline with pressure at 100-120 mmHg
Study: NCT03357978

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: bioelectrical impedance analysis
Description: Electrophysical measurement that allows to determine the exact composition of single body compartments by producing a magnetic field and detecting the potential difference through the body

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: blood draw
Description: Blood samples are taken from sober patients

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: transient elastography (FibroScan)
Description: FibroScan is a noninvasive tool to measure liver stiffness as an indication of fatty liver and liver fibrosis using ultrasound

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: ataxia score
Description: Klockgether ataxia score ranges from 0 to 35 points in which 0 means no symptoms and 35 stands for final stage of disease. It includes seven ataxia associated symptoms: dysarthria, intention tremor, ataxia of gait, stance, dysdiadochokinesia, upper limb and lower limb

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Five-Times-Sit-to-Stand Test
Description: The test measures the complete time which is necessary for an individual to stand up and sit down on a chair five times in series
Study: NCT03974698

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hemiarthroplasty
Description: Radiological features comparing the femoral stem position is measured on the postoperative x-ray. Presence of heterotopic ossification is assessed on the 12 months follow up.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hemiarthroplasty
Description: Radiological features comparing the femoral stem position is measured on the postoperative x-ray. Presence of heterotopic ossification is assessed on the 12 months follow up.
Study: NCT03112447

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: absorbable cartilage nail
Description: The experiment group patients were fixed with absorbable cartilage nails

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: traditional Kirschner wires
Description: The control group were fixed with traditional Kirschner wires
Study: NCT03379558

Intervention type: DRUG
Intervention: ALIROCUMAB SAR236553 (REGN727)
Description: Pharmaceutical form:as per routine practice Route of administration: subcutaneous
Study: NCT00436956

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging (DCE-MRI)
Description: Scans evaluate tumor tissue and blood flow.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD2171
Description: 20 mg oral daily for 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: 10mg orally daily in combination with AZD2171 20mg daily.
Study: NCT03650673

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Identification of subgroups of patients with early AD with risk of progression
Description: Clinical examination with questionnaires, Biological collection, Imaging (radiography, densitometry, ultrasound, and MRI)
Study: NCT03751436

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Given PO
Study: NCT00858715

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: aspirin
Description: 100 mg aspirin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: aspirin
Description: 100 mg aspirin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: clopidogrel
Description: 75 mg (Arm 1) and 150 mg (Arm 2)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: clopidogrel
Description: 75 mg (Arm 1) and 150 mg (Arm 2)
Study: NCT02454634

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IDH1 peptide vaccine
Study: NCT02200991

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LIXISENATIDE AVE0010
Description: Pharmaceutical form:solution Route of administration: subcutaneous

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sitagliptin
Description: Pharmaceutical form:tablet Route of administration: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin glargine HOE901
Description: Pharmaceutical form:solution Route of administration: subcutaneous

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin glargine HOE901
Description: Pharmaceutical form:solution Route of administration: subcutaneous
Study: NCT02525302

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HT-100
Description: HT-100 is Akashi Therapeutics' proprietary delayed-release formulation of halofuginone hydrobromide, a small molecule therapeutic with anti-fibrotic properties. May be administered in either fed or fasted state. Not mutation specific.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HT-100
Description: HT-100 is Akashi Therapeutics' proprietary delayed-release formulation of halofuginone hydrobromide, a small molecule therapeutic with anti-fibrotic properties. May be administered in either fed or fasted state. Not mutation specific.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HT-100
Description: HT-100 is Akashi Therapeutics' proprietary delayed-release formulation of halofuginone hydrobromide, a small molecule therapeutic with anti-fibrotic properties. May be administered in either fed or fasted state. Not mutation specific.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HT-100
Description: HT-100 is Akashi Therapeutics' proprietary delayed-release formulation of halofuginone hydrobromide, a small molecule therapeutic with anti-fibrotic properties. May be administered in either fed or fasted state. Not mutation specific.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HT-100
Description: HT-100 is Akashi Therapeutics' proprietary delayed-release formulation of halofuginone hydrobromide, a small molecule therapeutic with anti-fibrotic properties. May be administered in either fed or fasted state. Not mutation specific.
Study: NCT02854605

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GS-9674
Description: Tablet administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GS-9674
Description: Tablet administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to match GS-9674
Description: Tablet(s) administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to match GS-9674
Description: Tablet(s) administered orally once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to match GS-9674
Description: Tablet(s) administered orally once daily
Study: NCT01678599

Intervention type: DRUG
Group type: OTHER
Intervention: Benznidazole
Description: All patients participating in this study will be treated with Benznidazole, 5mg/Kg/day PO BID for 60 days with a maximum daily dose of 300mg, as per routine care provided by MSF in rural communities in Aiquile. For patients \> 60 kg, the total dose should be calculated (5mg/Kg x Weight x 60 days) and treatment duration should be adjusted/prolonged accordingly. This treatment is in accordance with the local recommendations from the Ministerio de Salud y Deportes de Bolivia.
Study: NCT03268018

Intervention type: DEVICE
Group type: OTHER
Intervention: Laser induced pressure wave calcium modification
Description: A calcium atherectomy and modification solution in patients with balloon resistant calcified lesions in infrainguinal disease. The intent is to both debulk and modify the vessel to restore blood flow, improve vessel compliance and drive better outcomes
Study: NCT01299415

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vadimezan™
Study: NCT01451554

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: portion control plate
Description: Individuals are provided with a portion control plate to use while eating and dietary counseling by dietician

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Usual Care
Description: self-help booklets
Study: NCT00607997

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vosaroxin
Description: Vosaroxin was administered by slow intravenous (IV) infusion or via syringe pump within 10 minutes.Patients could have completed up to 4 treatment cycles consisting of 1 or 2 induction treatment cycles and up to 2 consolidation treatment cycles. For Schedule A, an induction cycle was a minimum of 21 days during which patients received vosaroxin on Days 1, 8, and 15, followed by weekly observations until hematologic recovery for patients with aplastic marrow after the postinduction bone marrow assessment. For Schedules B and C, an induction cycle was a minimum of 15 days, during which patients received vosaroxin on Days 1 and 8 (Schedule B), or Days 1 and 4 (Schedule C), followed by the same weekly observations until hematologic recovery as for Schedule A.
Study: NCT03247361

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High-intensity IMT + Aerobic/resistance exercise
Description: High-intensity IMT

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low-intensity IMT + Aerobic/resistance exercise
Description: Low-intensity IMT

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham IMT + Aerobic/resistance exercise
Description: Aerobic and resistance exercise
Study: NCT05940077

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Community-based exercise involving non-contact boxing and individualized balance training
Study: NCT00248833

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 25ug Group B Meningococcal 44/76 MOS NOMV 5D Vaccine
Description: The study was conducted as a phase 1, outpatient, dose-escalating study for the Meningococcal 44/76 MOS NOMV 5D Vaccine (lot number 1119). 25µg with and without adjuvant were administered. Vaccinations were given intramuscularly at 0, 6, and 24 weeks.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 25ug Group B Meningococcal 44/76 MOS NOMV 5D Vaccine
Description: The study was conducted as a phase 1, outpatient, dose-escalating study for the Meningococcal 44/76 MOS NOMV 5D Vaccine (lot number 1119). 25µg with and without adjuvant were administered. Vaccinations were given intramuscularly at 0, 6, and 24 weeks.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 50ug Group B Meningococcal 44/76 MOS NOMV 5D Vaccine
Description: The study was conducted as a phase 1, outpatient, dose-escalating study for the Meningococcal 44/76 MOS NOMV 5D Vaccine (lot number 1119). 50µg without adjuvant was administered. Vaccinations were given intramuscularly at 0, 6, and 24 weeks.
Study: NCT03605849

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Centanafadine SR
Description: 200mg, BID, oral tablets
Study: NCT01353573

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Fixed Gantry Radiosurgery
Description: Single fraction radiosurgery will be prescribed using a fixed gantry radiosurgery delivery system

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Robotic Radiosurgery
Description: Single fraction radiosurgery will be prescribed using a robotic radiosurgery system
Study: NCT01329432

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Take care
Description: In TAKE CARE procedure all premature infants who suffered from respiratory distress syndrome (RDS) received 100 mg/kg of porcine surfactant preparation via an intratracheal catheter during spontaneous breathing.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: InSurE
Description: infants treated with InSurE procedure were intubated and ventilated to receive surfactant and placed on nCPAP rapidly after surfactant administration.
Study: NCT02368210

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 122-0551 Foam
Description: Topical Foam

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle Foam
Description: Topical Foam